Abeona Therapeutics Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Abeona Therapeutics Inc. (Nasdaq: ABEO) is a commercial-stage biopharmaceutical company developing and commercializing cell and gene therapies for serious rare diseases. The company offers ZEVASKYN (prademagene zamikeracel), the first and only FDA-approved autologous cell-based gene therapy for treating wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB); its development pipeline includes AAV-based gene therapies such as preclinical ABO-503 for X-linked retinoschisis (XLRS), ABO-504 for Stargardt Disease, and ABO-505 for autosomal dominant optic atrophy (ADOA), as well as partnered programs UX111 (Phase 1/2 for Sanfilippo syndrome type A with Ultragenyx Pharmaceutical Inc.), TSHA-102 (Phase 1/2 for Rett syndrome with Taysha Gene Therapies, Inc.), and TSHA-118 (Phase 1/2 for infantile Batten disease with Taysha Gene Therapies, Inc.); it leverages next-generation AIM capsid platform for enhanced tissue targeting in gene therapies and operates a fully integrated cGMP manufacturing facility for commercial production. Abeona Therapeutics, originally incorporated in 1972 as PlasmaTech Biopharmaceuticals, Inc. and rebranded in 2015 following acquisitions of Abeona Therapeutics LLC and Scioderm Inc., maintains headquarters in Cleveland, Ohio. Recent developments include FDA approval of ZEVASKYN and sale of its priority review voucher for $155 million, bolstering cash reserves to $207.5 million as of September 30, 2025 to fund operations beyond two years; first commercial patient treatments shifted to 4Q 2025 after optimizing release assay following a temporary biopsy pause; expansion of qualified treatment centers to three activated sites with over 30 eligible patients identified and growing demand; establishment of permanent CMS J-code effective January 2026 and coverage by major commercial payers covering 80% of insured lives; selection of ABO-503 into FDA Rare Disease Endpoint Advancement Pilot Program; and appointment of James A. Gow, MD, as Senior Vice President, Head of Clinical Development & Medical Affairs.
Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
Abeona Therapeutics Inc. (ABEO) Q1 2026 Earnings Call Transcript
Abeona Therapeutics Q1 Earnings Call Highlights
Abeona Reports Strong Q1 Revenue, Expands Treatment Center Network
Abeona Therapeutics® Reports First Quarter 2026 Results and Provides Pipeline Update
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Abeona Therapeutics® Announces Activation of Children's Hospital of Philadelphia as a New Qualified Treatment Center for ZEVASKYN®
Abeona Therapeutics® Announces Date of First Quarter Financial Results
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New York
LENZ Therapeutics (NASDAQ:LENZ) versus Abeona Therapeutics (NASDAQ:ABEO) Critical Comparison
Abeona Therapeutics: Maintaining 'Buy' On ZEVASKYN Launch Potential For RDEB
Abeona Therapeutics Inc. (ABEO) Q4 2025 Earnings Call Transcript
Abeona Therapeutics® Reports Full Year 2025 Financial Results and Corporate Updates
Abeona Therapeutics® Provides Business Update Highlighting Building Momentum in ZEVASKYN® Commercial Launch